Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elisha Fogel"'
Autor:
Ruwan Parakrama, Elisha Fogel, Carol Chandy, Titto Augustine, Matt Coffey, Lydia Tesfa, Sanjay Goel, Radhashree Maitra
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in co
Externí odkaz:
https://doaj.org/article/88cb56e4959547eb97786d26285e1c57
Publikováno v:
Cancer Management and Research
Elisha J Fogel,1 Avishai Samouha,1 Sanjay Goel,2 Radhashree Maitra1,2 1Department of Biology, Yeshiva University, New York, NY, 10033, USA; 2Albert Einstein College of Medicine at Montefiore Medical Center, Bronx, NY, 10461, USACorrespondence: Radhas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e6ea9310a2b1a425012d4f71d36596
https://doi.org/10.2147/cmar.s324203
https://doi.org/10.2147/cmar.s324203
Autor:
Imran Chaudhary, Elisha Fogel, Titto Augustine, Sanjay Goel, Radhashree Maitra, Rishika Nahata, Devika Rao, Thongthai Thavornwatanayong, Jeeshan Jiffry, Durvanand Saytoo, Hillary Guzik
Publikováno v:
Clin Cancer Res
Purpose: To explore the effects of pelareorep on autophagy in multiple models of colorectal cancer, including patient-derived peripheral blood mononuclear cells (PBMCs). Experimental Design: HCT116 [KRAS mutant (mut)] and Hke3 [KRAS wild-type (WT)] c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d51c73509769496fb6cc11632b1fb0
https://doi.org/10.1158/1078-0432.ccr-20-2385
https://doi.org/10.1158/1078-0432.ccr-20-2385
Publikováno v:
Journal of cellular immunology
In our recent publication [1], we have explored at the molecular level the consequences of reovirus administration to patients with KRAS mutated colorectal cancer (CRC). This was the first reported study where transcriptome assay was performed on KRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26168944a4588ac49382aaa2807c7004
http://europepmc.org/articles/PMC7793569
http://europepmc.org/articles/PMC7793569
Publikováno v:
J Oncol Res Ther
BACKGROUND: Approximately 45% of individuals diagnosed with Colorectal Cancer (CRC) also possess KRAS mutations. One developing therapeutic method for this disease is reovirus treatment. It is theorized that reovirus treatment on patients with KRAS m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c071eabfc1193b85b8aaa73b925e48a4
https://pubmed.ncbi.nlm.nih.gov/34841205
https://pubmed.ncbi.nlm.nih.gov/34841205
Autor:
Titto Augustine, Sanjay Goel, Lydia Tesfa, Carol Chandy, Radhashree Maitra, Ruwan Parakrama, Elisha Fogel, Matthew C. Coffey
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Background KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3895717a83bc855b11b8ba738183173e
https://doi.org/10.1186/s12885-020-07038-2
https://doi.org/10.1186/s12885-020-07038-2
Publikováno v:
Cancer Research. 81:2148-2148
Introduction: Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 40-45% of CRC patients possess KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patients possessing KRAS m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89dbdd1c8ab2426f6bc9b69295ac183e
https://doi.org/10.1158/1538-7445.am2021-2148
https://doi.org/10.1158/1538-7445.am2021-2148
Autor:
Radhashree Maitra, Devika Rao, Elisha Fogel, Jeeshan Jiffry, Sanjay Goel, Durvanand Saytoo, Thongthai Thavornwatanayong, Titto Augustine
Publikováno v:
Cancer Research. 79:4270-4270
Background: Oncolytic reovirus (REO), a promising player in cancer therapeutics targets transformed cells. The molecular mechanisms at play is yet to be defined. We hypothesize that reovirus implements its oncolytic properties by engaging the autopha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::239fa024b42db38d01bd962663d4bf15
https://doi.org/10.1158/1538-7445.am2019-4270
https://doi.org/10.1158/1538-7445.am2019-4270